@article{b532ddd2693a45faaec0e142235a0cb7,
title = "Incidence of premature battery depletion in subcutaneous cardioverter-defibrillator patients: insights from a multicenter registry",
abstract = "Background The subcutaneous ICD established its role in the prevention of sudden cardiac death in recent years. The occurrence of premature battery depletion in a large subset of potentially affected devices has been a cause of concern. The incidence of premature battery depletion has not been studied systematically beyond manufacturer-reported data.Methods Retrospective data and the most recent follow-up data on S-ICD devices from fourteen centers in Europe, the US, and Canada was studied. The incidence of generator removal or failure was reported to investigate the incidence of premature S-ICD battery depletion, defined as battery failure within 60 months or less.Results Data from 1054 devices was analyzed. Premature battery depletion occurred in 3.5% of potentially affected devices over an observation period of 49 months.Conclusions The incidence of premature battery depletion of S-ICD potentially affected by a battery advisory was around 3.5% after 4 years in this study. Premature depletion occurred exclusively in devices under advisory. This is in line with the most recently published reports from the manufacturer.",
keywords = "Subcutaneous ICD, Implantable cardioverter-defibrillator, Premature battery depletion, Longevity, Advisory, OUTCOMES, FAILURE",
author = "J. Luker and M. Strik and J.G. Andrade and A. Raymond-Paquin and M.H. Elrefai and P.R. Roberts and O.C. Perez and J. Kron and J. Koneru and H. Franqui-Rivera and A. Sultan and A. Ernst and J. Schmitt and A. Pott and C. Veltmann and N.T. Srinivasan and J. Collinson and {van Stipdonk}, A.M.W. and D. Linz and N. Fluschnik and T. Tonnis and A. Haeberlin and S. Ploux and D. Steven",
note = "Funding Information: Dr. Fluschik received grants from Biotronik and Medtronic not related to this work. Dr. Haeberlin has received travel fees/educational grants from Medtronic, Philips/Spectranetics and Biotronik without impact on his personal remuneration. He serves as a proctor for Medtronic. He is Co-founder and CEO of Act-Inno, a cardiovascular device testing company. Dr. Roberts has received Honoraria from Boston Scientific, Medtronic, and EBR systems Ltd. Dr. Elrefai has received research funding from Boston Scientific. Dr. Veltmann has received honoraria for lectures or consultant activity from Bayer, Biotronik, Medtronic, and Abbott. The remaining authors report no relevant conflict of interest in the context of this work. Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = jan,
day = "1",
doi = "10.1007/s10840-023-01468-1",
language = "English",
journal = "Journal of Interventional Cardiac Electrophysiology",
issn = "1383-875X",
publisher = "Springer",
}